•  
  •  
  •  
  •  

2023-09-29 05:26:25

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • WeP Solutions and FUJIFILM India ink a strategic partnership for India
  • Grand Mercure Agra Fatehabad Road, in the historic city of Agra, opens its doors
  • Apollo Hospitals Celebrates Its Leadership as the Largest Cardiac Center of Excellence
  • IndiGo announces new daily flights between Jaipur and Agra
  • Welspun India Ltd is now Welspun Living Ltd

Keywords Selected:  INE326A01037

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • Lupin's Joint Airways Initiative surpasses 10,000 Patients
  • Lupin acquires Five Brands from Menarini
  • Lupin Collaborates with Mark Cuban Cost Plus Drug Company and COPD Foundation to Expand Access to Medication for COPD Patients
  • Lupin Launches Propranolol Long-Acting Capsules to Improve Heart Health in Canada
  • Lupin Receives Approval from U.S. FDA for Pirfenidone Capsules
  • Lupin receives approval from U.S. FDA for Pirfenidone Tablets
  • Lupin acquires brands ONDERO® and ONDERO MET® to expand Diabetes Portfolio in India
  • Lupin Launches Tiotropium Dry Powder for Inhaler for the Treatment of COPD in the United States
  • Lupin launches Jeet, a Patient Support Program to raise awareness of Cardiovascular Disease among Patients
  • Lupin receives approval from U.S. FDA for Metoprolol Succinate Extended-Release Tablets USP
  • Lupin receives approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.09%
  • Lupin receives approval from U.S. FDA for Doxycycline Hyclate Delayed-Release Tablets USP
  • Lupin's Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations
  • Lupin receives approval from U.S. FDA for Fluocinolone Acetonide Body Oil
  • Lupin receives approval from U.S. FDA for Fluocinolone Acetonide Topical Oil
  • Lupin receives approval from US FDA for Turqoz®
  • Lupin receives approval from TGA Australia for Tiotropium Dry Powder for Inhaler for Treatment of COPD
  • Lupin receives tentative approval from U.S. FDA for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets
  • Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment in Germany
  • Lupin receives approval from U.S. FDA for Chlorpromazine Hydrochloride Tablets USP
  • Lupin's Nagpur Oral Solid Dosage facility gets 2 observations from USFDA
  • Lupin receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility
  • Lupin receives Tentative Approval from U.S. FDA for Dolutegravir Tablets for Oral Suspension
  • Lupin receives approval from U.S. FDA for Cyanocobalamin Nasal Spray

Latest Post

  • WeP Solutions and FUJIFILM India ink a strategic partnership for India
  • Grand Mercure Agra Fatehabad Road, in the historic city of Agra, opens its doors
  • Apollo Hospitals Celebrates Its Leadership as the Largest Cardiac Center of Excellence
  • IndiGo announces new daily flights between Jaipur and Agra
  • Welspun India Ltd is now Welspun Living Ltd


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2022